Internal Medicine, Pulmonary Disease · Utica, NY
NPI
1003892134
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
35 Riverside Dr
Utica, NY, 13502
Phone (315) 735-2294
Groups this clinician bills Medicare through
Medicare paid, 2024
$90K
1,378 services
Medicare patients, 2024
490
Average age 75
Drug cost, 2024
$2.2M
2,901 prescriptions
Company payments, 2025
$79.59
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nalini J Namassivaya was code 99232 (hospital e&m - subsequent), 275 times for 118 patients. In total Nalini J Namassivaya billed 1,378 services in 25 codes, and Medicare paid $90K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-08-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 275 | 118 | $63.56 | $17K |
| 99214 Office E&M - Established | Office | 153 | 113 | $70.80 | $11K |
| 99213 Office E&M - Established | Office | 140 | 118 | $46.37 | $6,492 |
| 99233 Hospital E&M - Subsequent | Facility | 137 | 63 | $96.60 | $13K |
| 94726 Pulmonary Function Testing | Office | 111 | 111 | $8.70 | $966 |
| 94729 Pulmonary Function Testing | Office | 110 | 110 | $6.62 | $728 |
| 99291 Critical Care E&M | Facility | 110 | 47 | $169.90 | $19K |
| 94060 Pulmonary Function Testing | Office | 106 | 106 | $7.62 | $808 |
| 99223 Hospital E&M - Initial | Facility | 69 | 68 | $134.92 | $9,309 |
| 99222 Hospital E&M - Initial | Facility | 55 | 55 | $106.02 | $5,831 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 28 | 28 | $13.48 | $377 |
| 99442 Telephone Services | Office | 21 | 21 | $68.08 | $1,430 |
| 99231 Hospital E&M - Subsequent | Facility | 14 | 12 | $35.55 | $498 |
By year: 2022 $118K for 1,891 services; 2023 $121K for 1,475 services; 2024 $90K for 1,378 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nalini J Namassivaya prescribed most often to Medicare patients was Montelukast Sodium, with 439 prescriptions and refills. In total Nalini J Namassivaya wrote 2,901 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 439 | 930 | 109 | $5,213 |
| Prednisone Generic | 338 | 520 | 137 | $1,648 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 330 | 411 | 95 | $16K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 289 | 698 | 86 | $418K |
| Azithromycin Generic | 288 | 582 | 104 | $7,805 |
| Breo Ellipta Fluticasone/Vilanterol | 112 | 227 | 27 | $82K |
| Incruse Ellipta Umeclidinium Bromide | 78 | 166 | 18 | $51K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 77 | 147 | 24 | $81K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 70 | 160 | 15 | $69K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 68 | 140 | 21 | $17K |
| Ventolin Hfa Albuterol Sulfate | 66 | 88 | 15 | $5,622 |
| Ofev Nintedanib Esylate | 60 | 76 | Under 11 | $808K |
| Tiotropium Bromide Generic | 52 | 98 | 13 | $33K |
| Symbicort Budesonide/Formoterol Fumarate | 52 | 98 | 25 | $21K |
| Spiriva Respimat Tiotropium Bromide | 48 | 92 | 16 | $46K |
Brand drugs: 1,365 claims; generic drugs: 1,536 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nalini J Namassivaya $79.59 ($79.59 in general payments such as food, travel and fees) from 3 companies. The largest payer was GlaxoSmithKline, LLC. with $42.77.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.